You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Sample-free onsite detection of cocaine using microneedles via laser-treated skin

    SBC: AFASCI, INC.            Topic: NIDA

    DESCRIPTION provided by applicant The abuse of illicit drugs such as cocaine marijuana and heroin remains a critical public health concern throughout the country and is associated with staggering economic and social consequences Cocaine remains the most frequently recorded illicit drug in emergency hospital visits and the leading cause of drug related deaths in the United States Since as hi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Magnetic levitation motor for pediatric cardiac and cardiopulmonary therapies

    SBC: ENSION Inc            Topic: NHLBI

    Abstract This Phase I STTR application proposes development of an innovative low cost magnetic levitation motor specifically designed for pediatric extracorporeal cardiac and cardiopulmonary therapies Magnetic levitation enables contact free impeller operation thereby eliminating critical areas of wear and heat generation that can contribute to hemolysis and thrombosis The extracorporeal pedia ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. CardioPort to Enable Intracardiac Beating Heart and Minimally Invasive Open Heart Surgery

    SBC: Nido Surgical, Inc            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe goal of this Fast Track STTR project is to develop a novel CardioPortTM surgical device that will enable minimally invasive beating heart repair without use of cardiopulmonary bypassCPBThere is a critical unmet need for new instruments to improve the surgical repair of heart defects in childrenCurrent best surgical practices involve either open heart surgery wit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. SMALL MOLECULE ANTAGONISTS OF PF FOR THE TREATMENT AND PREVENTION OF HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    DESCRIPTION provided by applicant We have discovered the first ever inhibitors of PF a platelet protein central to the pathophysiology of heparin induced thrombocytopenia HIT Heparin is a naturally occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature and major medical applications of heparin include dialysis cardiac catheteri ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Peptide Based Therapy for Lung Fibrosis

    SBC: Novici Biotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Optimized AAV Serotype Vectors for Human Gene Therapy

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Novel therapies for inherited muscle diseases

    SBC: Medosome Biotec, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government